MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Disease-modifying strategies"

  • MDS Virtual Congress 2021

    Parkinson Progression Marker Initiative – New Science/New Cohorts

    K. Marek, A. Siderowf, T. Simuni, L. Chahine, K. Kieburtz, B. Mollenhauer, D. Galasko, K. Merchant, E. Brown, C. Coffey, R. Dobkin, T. Foroud, K. Poston, E. Flagg, S. Chowdhury, C. Tanner (New Haven, USA)

    Objective: The Parkinson Progression Marker Initiative (PPMI) is expanding its cohorts and exploring additional biomarkers of PD progression to test hypotheses of the underlying molecular…
  • MDS Virtual Congress 2021

    Informing the design of disease modifying trials for Parkinson’s disease – A Delphi study

    M. Zeissler, R. Windle, K. Raphael, G. Rafaloff, K. Mcfarthing, H. Matthews, C. Carroll (Plymouth, United Kingdom)

    Objective: To assemble an international, multi-stakeholder Delphi panel to seek consensus on trial methodology for an adaptive trial platform investigating disease modifying therapies (DMTs) in…
  • MDS Virtual Congress 2021

    STATINS IN PARKINSON’S DISEASE: INFLUENCE ON MOTOR PROGRESSION

    G. Palermo, S. Giannoni, M. Giuntini, E. Belli, D. Frosini, G. Siciliano, R. Ceravolo (Pisa, Italy)

    Objective: To evaluate whether long-term statin use may affect motor progression in a large cohort of de novo patients with Parkinson's Disease. Background: Statins are…
  • MDS Virtual Congress 2021

    Attitudes on therapy-associated risks in individuals with multiple system atrophy and Parkinson’s disease and their views on aspects of clinical trials

    AM. Bernhardt, T. Barthel, I. Friedrich, E. Kocakavuk, E. Nachman, M. Oeller, K. Peikert, M. Roderigo, A. Rossmann, LO. Wilhelm, M. Brandt, J. Classen, BH. Falkenburger, A. Frank, L. Hoegner, H. Jacobi, A. Janzen, S. Katzdobler, J. Nieweler, T. Prell, JJ. Rumpf, C. van Riesen, T. Warnecke, M. Weiler, F. Gandor, J. Levin, A. Giese, WH. Oertel (Munich, Germany)

    Objective: To assess risk attitudes of patients suffering from multiple system atrophy (MSA) and Parkinson’s disease (PD) on future disease-modifying therapies as well as related…
  • MDS Virtual Congress 2021

    Rapamycin attenuates nigral and hippocampal alpha-synuclein accumulation in AAV-mediated alpha-synuclein overexpression model of Parkinson’s disease

    E. Cinar, G. Yalcin-Cakmakli, A. Ulusoy, E. Saka, B. Tel, B. Elibol (Zonguldak, Turkey)

    Objective: To examine the possible neurorestorative effects of chronic rapamycin treatment in AAV-mediated alpha-synuclein (a-syn) overexpression model of Parkinson’s disease (PD), designed to induce hippocampal…
  • MDS Virtual Congress 2020

    Cardiac Safety of PBT434, an Inhibitor of Alpha-Synuclein Aggregation for the Treatment of Multiple System Atrophy (MSA)

    D. Stamler, M. Bradbury, C. Wong, E. Offman (Newark, CA, USA)

    Objective: Evaluate potential cardiac liability of PBT434 using concentration-response and outlier analyses of ECG and pharmacokinetic (PK) data from a Phase 1 study of PBT434…
  • MDS Virtual Congress 2020

    New tool to localize seizure onset zone from sEEG signal-connectivity epileptogenicity index

    A. Balatskaya (Moscow, Russian Federation)

    Objective: The main diagnostic challenge of drug resistant epilepsies is to find epileptogenic zone, which will be enough to remove to reach seizure freedom. These…
  • MDS Virtual Congress 2020

    Remote monitoring of physical activity in Veterans with Parkinson’s disease

    K. Waddell, S. Wood, S. Koganti, J. Morley (Philadelphia, PA, USA)

    Objective: To determine the feasibility of a remote physical activity monitoring program for Veterans with Parkinson’s disease (PD). Background: Regular physical activity improves overall health,…
  • MDS Virtual Congress 2020

    Association Between Diet & Parkinson’s Disease Progression

    L. Mischley, J. Farahnik (Kenmore, WA, USA)

    Objective: The objective of this study was to evaluate whether food choices are associated with patient-reported Parkinson's disease (PD) severity over time. Background: Several traditional…
  • MDS Virtual Congress 2020

    Translatable biomarkers in gene therapy for Huntington’s Disease: learnings from pre-clinical studies

    A. Valles, M. Evers, A. Stam, M. Sogorb-Gonzales, C. Brouwers, C. Vendrell, S. Acar-Broekmans, V. Fodale, A. Bresciani, R. Nieuwland, Z. Ellederova, J. Motlik, M. de Haan, B. Leavitt, S. van Deventer, P. Konstantinova (Amsterdam, Netherlands)

    Objective: We have developed AAV5-miHTT, a recombinant AAV-based gene therapy expressing an engineered microRNA that specifically binds to HTT exon1, resulting in lowering of both…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley